ClinicalTrials.gg
Active, not recruitingNCT05147220Updated Aug 18, 2026

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

A Phase 3 interventional study of Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 200 sites in 34 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Read the detailed description

The study CLOU064C12301 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.

The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).

The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.

A second study of identical design (CLOU064C12302) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.

02

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

Keywords

  • MS
  • RMS
  • RRMS
  • active secondary progressive multiple sclerosis SPMS
  • remibrutinib
  • LOU064
  • teriflunomide
  • adult
  • relapse
  • Expanded Disability Status Scale
  • T2 lesions
  • T1 lesions
  • GD- enhancing MRI
  • Neurofilament light chain
  • McDonald diagnostic criteria
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • 18 to 55 years of age
  • Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
  • At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
  • EDSS score of 0 to 5.5 (inclusive)
  • Neurologically stable within 1 month

Exclusion Criteria:

  • Diagnosis of primary progressive multiple sclerosis (PPMS)
  • Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening
  • History of CNS disease other than MS
  • Ongoing substance abuse (drug or alcohol)
  • History of of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),
  • Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML
  • suicidal ideation or behavior
  • Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence
  • Participants who have had a splenectomy
  • Active clinically significant systemic bacterial, viral, parasitic or fungal infections
  • Positive results for syphilis or tuberculosis testing
  • Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral
  • Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.
  • Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for antibody
  • History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis (including all classes) or hepatic failure or any chronic liver or biliary disease.
  • History of severe renal disease or creatinine level
  • Participants at risk of developing or having reactivation of hepatitis
  • Hematology parameters at screening:

    • : \< 10 g/dl (\<100g/L)
    • : \< 100000/mm3 (\<100 x 109/L)
    • Absolute lymphocyte count \< 800/mm3 (\<0.8 x 109/L)
    • White blood cells: \<3 000/mm3 (\<3.0 x 109/L)
    • Neutrophils: \< 1 500/mm3 (\<1.5 x 109/L)
    • B-cell count \< 50% lower limit of normal (LLN) or total IgG \& total IgM \< LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
  • History or current diagnosis of significant abnormalities
  • Resting ≥450 msec (male) or ≥460 msec (female) at pre-treatment as per central ECG reading at screening visit
  • Use of other drugs
  • Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,
  • History of gastrointestinal bleeding
  • Major surgery within 8 weeks prior to screening
  • History of to any of the study drugs or
  • Pregnant or nursing (lactating) female participants, prior to randomization
  • Women of not using highly effective
  • Sexually active males not agreeing to use condom
  • Have received any live or within 6 weeks of randomization or requirement to receive these vaccinations during study
  • Use of strong inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization

Inclusion to Extension part:

  • Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)

Other inclusion and exclusion criteria may apply

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,000 participants (actual)

Study arms

  • Experimental
    Remibrutinib - Core

    Remibrutinib tablet and matching placebo of teriflunomide capsule

    Drug: Remibrutinib

  • Active comparator
    Teriflunomide - Core

    Teriflunomide capsule and matching placebo remibrutinib tablet

    Drug: Teriflunomide

  • Experimental
    Remibrutinib - Extension

    Participants on remibrutinib in Core will continue on remibrutinib tablet

    Drug: Remibrutinib

  • Experimental
    Remibrutinib - Extension (on teriflunomide in Core)

    Participants on teriflunomide in Core will switch to remibrutinib tablet

    Drug: Remibrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Annualized relapse rate (ARR) of confirmed relapses [Core Part]

    ARR is the average number of confirmed MS relapses in a year

    Time frame: From Baseline, up to 30 months

Secondary outcomes

  1. Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)

    Time to 3-month confirmed disability progression (3mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months

    Time frame: Baseline up to 30 months

  2. Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)

    Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months

    Time frame: Baseline up to 30 months

  3. Annualized rate of new or enlarging T2 lesion [Core Part]

    Number of new/newly enlarged T2 lesions per year

    Time frame: Baseline up to 30 months

  4. Neurofilament light chain (Nfl) [Core Part]

    Neurofilament light chain (NfL) concentration in serum

    Time frame: Baseline up to 30 months

  5. Number of Gd-enhancing T1 lesions per MRI scan [Core Part]

    Average number of Gd-enhancing T1 lesions per scan

    Time frame: Baseline up to 30 months

  6. Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)

    Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI

    Time frame: Baseline up to 30 months

  7. Time to first confirmed relapse [Core Part]

    Change in the Expanded Disability Status Scale (EDSS), an increase of at least 0.5 points on the EDSS (total) score, or an increase of at least 1 point on at least two functional scores (FSs), or an increase of at least 2 points on at least one FS, excluding changes involving bowel/bladder or cerebral FS, compared to the previous available rating.

    Time frame: Baseline up to 30 months

  8. Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)

    Decrease in Expanded Disability Status Scale Score (EDSS) which is sustained for at least 6 months

    Time frame: Baseline up to 30 months

  9. Time to 3-months confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) independent of relapse activity (PIRA) [Core Part] (pooled data)

    Time to 3-month confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months or 6 months, respectively, without an on-study relapse before or on the day of a progression event.

    Time frame: Baseline up to 30 months

  10. Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)

    Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening

    Time frame: Baseline up to 30 months

  11. Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)

    The patient walking speed to cover 25-foot distance is recorded in seconds. Longer time indicates poorer lower limb function. 20% worsening is defined as 20% increase from baseline T25FW score

    Time frame: Baseline, up to 30 months

  12. Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)

    The patient's right and left arm function to peg 9 holes measured in seconds. Longer time indicates poorer upper limb function. 20% worsening is defined as 20% increase from baseline 9HPT score in at least one hand (average of two trials per hand)

    Time frame: Baseline up to 30 months

  13. Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)

    The composite involves CDP and worsening by at least 20% in T25FW and 9HPT

    Time frame: Baseline up to 30 months

  14. Change from Baseline in T2 lesion volume [Core Part]

    Change from baseline in total T2 lesion volume.

    Time frame: Baseline up to 30 months

  15. Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]

    29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life

    Time frame: Baseline up to 30 months

  16. Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]

    Adverse events and SAEs including clinically significant , laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating

    Time frame: Baseline up to 30 months

  17. Pharmacokinetics of remibrutinib [Core Part]

    Blood concentrations of remibrutinib

    Time frame: Month 1, Month 6

  18. Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]

    Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating

    Time frame: Day 1 Extension up to 5 years

  19. Annualized relapse rate (ARR) of confirmed relapses [Extension Part]

    ARR is the average number of confirmed MS relapses in a year

    Time frame: Day 1 Extension up to 5 years

  20. Annualized rate of new or enlarging T2 lesion [Extension Part]

    Number of new/newly enlarged T2 lesions per year

    Time frame: Day 1 Extension up to 5 years

  21. Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]

    Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months

    Time frame: Day 1 Extension up to 5 years

  22. Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]

    Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening

    Time frame: Day 1 Extension up to 5 years

  23. Neurofilament light chain (NfL) [Extension Part]

    Neurofilament light chain (NfL) concentration in serum

    Time frame: Day 1 Extension up to 5 years

  24. Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part]

    29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life

    Time frame: Day 1 Extension up to 5 years

07

Study locations

200 sites
  • AZ Integrated Neuro and Spine
    Phoenix, Arizona 85037, United States
  • Center for Neurosciences
    Tucson, Arizona 85718, United States
  • The Belinga Clinic
    Fort Smith, Arkansas 72916, United States
  • The Research and Education Inst of Alta Bates Summit Med Grp
    Berkeley, California 94705, United States
  • The Neuron Clinic
    Chula Vista, California 91910, United States
  • Glendale Adventist Medical Center
    Glendale, California 91206, United States
  • Hoag Health System
    Newport Beach, California 92663, United States
  • SC3 Research Pasadena
    Pasadena, California 91105, United States
  • Neuro Center
    Pomona, California 91767, United States
  • Alpine Clinical Research Center
    Boulder, Colorado 80301, United States
  • Christiana Care Health Services
    Newark, Delaware 19713, United States
  • Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • Neurology of Central FL Res Ctr
    Altamonte Springs, Florida 32714, United States
  • Arrow Clinical Trials
    Daytona Beach, Florida 32117, United States
  • Homestead Assoc In Research Inc
    Homestead, Florida 33033, United States
  • Reliant Medical Research
    Miami, Florida 33165, United States
  • Neurological Services of Orlando PA
    Orlando, Florida 32806, United States
  • Orlando Health Clinical Trials
    Orlando, Florida 32806, United States
  • Comprehensive Neurology Clinic
    Orlando, Florida 32825, United States
  • Neurology Associates of Ormond Beach
    Ormond Beach, Florida 32174, United States
  • Neurostudies Inc
    Port Charlotte, Florida 33952, United States
  • Accel Research Sites St Pete-Largo
    Seminole, Florida 33777, United States
  • University Of South Florida
    Tampa, Florida 33612, United States
  • Conquest Research
    Winter Park, Florida 32789, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • IU Health Inc
    Fort Wayne, Indiana 46815, United States
  • College Park Family Care Center
    Overland Park, Kansas 66210, United States
  • Norton Neurology MS Services
    Louisville, Kentucky 40207, United States
  • American Oncology Partners PA Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Neurology Center of New England PC
    Foxborough, Massachusetts 02035, United States
  • Wayne State University Multiple Sclerosis Clinic
    Detroit, Michigan 48201, United States
  • The MS Center for Innovation in Care
    St Louis, Missouri 63131, United States
  • SCL Health
    Billings, Montana 59101, United States
  • Jersey Shore University Medical Ctr
    Neptune City, New Jersey 07753, United States
  • Neurological Associates of Long Island PC
    Lake Success, New York 11042, United States
  • NYU Langone Med Center CV Research
    New York, New York 10016, United States
  • The Neurological Institute PA
    Charlotte, North Carolina 28204, United States
  • Velocity Clinical Research
    Raleigh, North Carolina 27607, United States
  • Columbus Neuroscience
    Westerville, Ohio 43082, United States
  • Multiple Sclerosis Center of Excellence of OMRF
    Oklahoma City, Oklahoma 73104, United States
  • Providence St Vincent Med Center
    Portland, Oregon 97225, United States
  • University Of Pittsburgh Medical Ctr Magee-Womens Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Reading Hospital
    Reading, Pennsylvania 19611, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Texas Neurology
    Dallas, Texas 75206, United States
  • John Peter Smith Hospital
    Fort Worth, Texas 76104, United States
  • Neuro Eye Clinical Trials Inc
    Houston, Texas 77074, United States
  • DHR Health Institute
    McAllen, Texas 78504, United States
  • Saturn Research Solutions LLC
    Plano, Texas 75024, United States
  • MS Center of Greater Washington, P.C.
    Vienna, Virginia 22182, United States
  • University of Wisconsin Madison
    Madison, Wisconsin 53792, United States
  • Neuroscience Group
    Neenah, Wisconsin 54956, United States
  • Novartis Investigative Site
    Capital Federal, Buenos Aires 1424, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province 2000, Argentina
  • Novartis Investigative Site
    Santiago del Estero, Santiago del Estero Province 4200, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1055AAF, Argentina
  • Novartis Investigative Site
    Caba, C1182, Argentina
  • Novartis Investigative Site
    Caba, C1424BYD, Argentina
  • Novartis Investigative Site
    Capital Federal, C1023AAB, Argentina
  • Novartis Investigative Site
    Linz, Upper Austria 4020, Austria
  • Novartis Investigative Site
    Linz, 4020, Austria
  • Novartis Investigative Site
    Brussels, Brussels Capital 1070, Belgium
  • Novartis Investigative Site
    Bruges, 8000, Belgium
  • Novartis Investigative Site
    Edegem, 2650, Belgium
  • Novartis Investigative Site
    Melsbroek, 1820, Belgium
  • Novartis Investigative Site
    Overpelt, 3900, Belgium
  • Novartis Investigative Site
    Porto Alegre, Porto Alegre RS 90610 000, Brazil
  • Novartis Investigative Site
    Santo André, São Paulo 09040 010, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 01244-030, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 04076-004, Brazil
  • Novartis Investigative Site
    São Paulo, 01321001, Brazil
  • Novartis Investigative Site
    São Paulo, 04550-000, Brazil
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Sofia, 1113, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Sofia, 1680, Bulgaria
  • Novartis Investigative Site
    Santiago, Santiago Metropolitan 7650568, Chile
  • Novartis Investigative Site
    Santiago, Santiago Metropolitan 8431657, Chile
  • Novartis Investigative Site
    Guangzhou, Guangdong 510030, China
  • Novartis Investigative Site
    Zhengzhou, Henan 450003, China
  • Novartis Investigative Site
    Changsha, Hunan 410008, China
  • Novartis Investigative Site
    Baotou, Inner Mongolia 014040, China
  • Novartis Investigative Site
    Hohhot, Inner Mongolia 010017, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Beijing, 100053, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Chongqing, 400016, China
  • Novartis Investigative Site
    Tianjin, 300052, China
  • Novartis Investigative Site
    Puerto Colombia, Atlántico 080012, Colombia
  • Novartis Investigative Site
    Cali, Valle del Cauca Department 760001, Colombia
  • Novartis Investigative Site
    Cali, Valle del Cauca Department 760032, Colombia
  • Novartis Investigative Site
    Bogotá, 111411, Colombia
  • Novartis Investigative Site
    Medellín, 050001, Colombia
  • Novartis Investigative Site
    Medellín, 050034, Colombia
  • Novartis Investigative Site
    Zagreb, Croatia 10000, Croatia
  • Novartis Investigative Site
    Osijek, 31000, Croatia
  • Novartis Investigative Site
    Rijeka, 51000, Croatia
  • Novartis Investigative Site
    Zagreb, 10000, Croatia
  • Novartis Investigative Site
    Slagelse, 4200, Denmark

Showing the first 100 of 200 sites across 34 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jul 2026, 55 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2021
First posted
Dec 7, 2021
StartActual
Dec 16, 2021
Primary completionActual
Jul 21, 2026
CompletionEst.
Oct 30, 2030
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05147220
Responsible party
Sponsor
First posted
Dec 7, 2021
Start date
Dec 16, 2021
Primary completion
Jul 21, 2026
Completion
Oct 30, 2030 (estimated)
Last update
Aug 18, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion